Can Better Biomarkers Reduce Drug Failure?

How next-generation biomarker strategies could improve patient stratification, strengthen clinical trials, and reduce the cost of drug development

1

Roughly 9 in 10 drugs entering clinical trials fail to reach the market, contributing to drug development costs.
2

Single biomarkers and poorly defined trial populations can obscure treatment effects in subgroups that might respond.
3

Biomarker constellations across biological layers, analyzed with tools such as AI and machine learning, may improve patient stratification.
4

NMR spectroscopy can convert blood or urine biomarker data into digital data for repeated analysis without additional sample processing.
5

Less invasive liquid biopsies and digital monitoring can provide more frequent assessments and may reduce travel burdens for trial participants.

1